Long-acting IL-7 drug trial for low CD4 immune cells
Part of Blood & lymphatic, Immune system & allergy, Infections clinical trials.
This Phase 1/2 study tests a long-acting IL-7 medicine to raise low CD4 immune cells in people with idiopathic CD4 lymphopenia. Because this is a dose-escalation study, the goal is to check safety and see if the treatment affects immune cell levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 75 years old
- Be able to sign consent and agree to study procedures
- Already enrolled in a related NIH study called EPIC (NCT0086726)
- Have a history of low CD4 counts (<300) on at least two tests 6+ weeks apart
- If you can get pregnant or make someone pregnant, use strong birth control or stay abstinent starting before injections and for 30 days after the last dose
- Not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests how safe belimumab is for people with idiopathic CD4 lymphopenia (low protective white blood cells) and signs of autoantibodies. It aims to learn whether the treatment is tolerable and could be a future option for people with this immune condition.
This study collects blood-forming cells from people with low CD4 counts and healthy volunteers to learn how the immune system works. It may help researchers better understand and treat conditions like idiopathic CD4 lymphocytopenia.
This study looks for what causes and how idiopathic low CD4 cells happen over time, using blood and tissue samples. It may help doctors learn why this occurs and how to better track people with it.
This trial tests a new gene therapy that uses a person's own blood stem cells and T cells, which are corrected with a gene-editing tool called base editing. It is designed for people with a specific CD40L gene mutation who also have liver problems and portal hypertension. The goal is to see if this treatment can improve their immune system and liver health.
This trial tests a new drug called JL18008 (a man-made form of Interleukin-7) to see if it can help increase CD4 immune cells in people with HIV who are on effective antiretroviral therapy but have persistently low CD4 counts (between 100 and 350). It aims to improve immune function.
This study tests an experimental drug called JL18008 in people with HIV who have been on stable HIV medications for years but whose immune systems (CD4 cells) haven't recovered as expected. The drug may help boost immune function in these patients.
Hear when a new Idiopathic CD4 Lymphopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.